Mesenchymal stromal cell therapy for acute respiratory distress syndrome due to coronavirus disease 2019

BACKGROUND AIMS: The acute respiratory distress syndrome (ARDS) resulting from coronavirus disease 2019 (COVID-19) is associated with a massive release of inflammatory cytokines and high mortality. Mesenchymal stromal cells (MSCs) have anti-inflammatory properties and have shown activity in treating...

Descripción completa

Detalles Bibliográficos
Autores principales: Whittaker Brown, Stacey-Ann, Iancu-Rubin, Camelia, Aboelela, Adam, Abrahams, Alex, Burke, Elizabeth, Drummond, Tiffany, Grossman, Fred, Itescu, Silviu, Lagdameo, Jonathan, Lin, Jung-Yi, Mark, Alexis, Levine, John E., Osman, Keren
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Inc. on behalf of International Society for Cell & Gene Therapy. 2022
Materias:
Full-Length Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8995321/
https://www.ncbi.nlm.nih.gov/pubmed/35649958
http://dx.doi.org/10.1016/j.jcyt.2022.03.006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8995321/
https://www.ncbi.nlm.nih.gov/pubmed/35649958
http://dx.doi.org/10.1016/j.jcyt.2022.03.006

Ejemplares similares